Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at

Center for HIV/AIDS Vaccine Immunology & Immunogen Discovery (CHAVI-ID)

CHAVI-ID are two consortiums established by NIAID to undertake the immunologic research required to tackle the major scientific obstacles in the development of an effective HIV vaccine. The two seven-year awards were made in 2012, one to Duke University and a second to The Scripps Research Institute.

Main Areas of Focus

  • To determine the viral and immunological events and host genetic factors associated with HIV transmission, infection and (partial) containment of virus replication
  • To develop novel HIV-1 vectors, immunogens and adjuvants that suppress viral replication and elicit persistent mucosal and/or systemic immune responses
  • To use SIV infection in primates as a model for HIV infection in humans and determine the factors that lead to mucosal protection from SIV in primates
  • To test novel HIV-1 vaccine candidates in phase I clinical trials
Content last reviewed on November 17, 2017